Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET
Company Participants
Mark Jacobson - Investor Relations
Herriot Tabuteau - Chief Executive Officer
Nick Pizzie - Chief Financial Officer
Lori Englebert - Executive Vice President, Commercial and Business Development
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Marc Goodman - SVB Securities
David Amsellem - Piper Sandler
Joon Lee - Truist Securities
Vikram Purohit - Morgan Stanley
Yatin Suneja - Guggenheim Partners
Joseph Thome - TD Cowen
Graig Suvannavejh - Mizuho Securities
Myles Minter - William Blair
Matt Kaplan - Ladenburg Thalmann
Boobalan Pachaiyappan - H.C. Wainwright
Operator
Hello and welcome to the Axsome Therapeutics First Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Mark Jacobson. Please go ahead, Mark.
Mark Jacobson
Thank you, operator. Good morning and thank you all for joining us on today’s conference call. This morning, we issued our earnings press release providing a corporate update and details of the company’s financial results for the first quarter of 2023. The release crossed the wire a short time ago and is available on our website at axsome.com.
During today’s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct in the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding Sunosi, Auvelity and our pipeline products, revenue projections and possible intended use of cash and investments. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today’s date, and the company disclaims any obligation to update such statements.
Joining me on the call today are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; and Lori Englebert, Executive Vice President of Commercial and Business Development. Herriot will provide an overview of the company and progress made in the first quarter of 2023 as well as upcoming milestones. Following Herriot, Nick will review our financial results and then Lori will provide a commercial update. We will then open the line for questions. Questions will be taken in the order they are received.